Tyler Merkeley, CARB-X co-founder and program director for ASPR’s Biomedical Advanced Research and Development Authority, describes the drivers and next steps in creating a diverse portfolio Powered by CARB-X, one of the world’s largest public-private partnerships dedicated to accelerating development of innovative antibacterial drugs, diagnostics, and devices.

 

 

 

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *